1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Cancer Drug News 26 OCTOBER 2015

Cancer Drug News 26 OCTOBER 2015

  • October 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Optimal Legacy/Innovation Balance To Maintain Roche's Growth Trajectory
Industry Brief - Spectrum Receives Evomela CRL From FDA
Industry Brief - Synta Terminates Ganetespib Phase III Trial In Lung Cancer
Industry Brief - Exelixis Initiates Cabozantinib Rolling NDA Submission For RCC In US
Industry Brief - Atara Bio's Activin Inhibitor Gains FDA ODD For OC
Industry Brief - MacroGenics/Merck Enter Immuno-Oncology Clinical Trial Collaboration
Industry Brief - Onivyde Approved In Taiwan For MPC
Industry Brief - Amgen Gains Positive CHMP Positive For Imlygic
Industry Brief - FDA Approves Yondelis For LPS/LMS
Industry Trend Analysis - Collaborative Approach Will Bolster AstraZeneca/Lilly's Immuno-Oncology Presence
Industry Brief - NW Bio Raises Funds To Advance DCVax-L/DCVax-Direct Programmes
Industry Trend Analysis - Greater Knowledge Application Boosting Cancer Vaccine Potential
Industry Brief - Nuevolution/Janssen Enter Drug Discovery Collaboration
Industry Brief - Symphogen Raises Funds To Advance Oncology Pipeline
Industry Trend Analysis - Novartis Maximising Chances Of Immuno-oncology Success
Industry Brief - Cancer Conferences - January 2016

Table Of Contents

Cancer Drug News 26 OCTOBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • $ 6995
  • Industry report
  • November 2016
  • by Global Data

Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident ...

Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Hematological Malignancies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Hematological Malignancies Market: Overview This report provides in-depth region wise and country wise analysis of the hematological malignancies market. Stakeholders of this report include manufacturers ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.